Source-grounded facts extracted from Alector, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Alector, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-17 meeting.
“3. Stockholders approved, on a non-binding advisory basis, the compensation of Alector’s named executive officers as disclosed in the proxy statement for the Annual Meeting, known as the Say-on-Pay vote. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Vote 58,652,335 2,492,538 11,082 36,697,144”
Alector, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
“2. Stockholders ratified the appointment of Ernst & Young LLP as Alector’s independent registered accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Vote 97,717,750 52,302 83,047 0”
Alector, Inc. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.
“1. The Class II director nominees were elected to serve until Alector’s 2029 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Vote Elizabeth Garofalo, M.D. 60,256,636 899,318 36,697,144 Errol De Souza, Ph.D. 60,461,939 694,016 36,697,144 Kristine Yaffe, M.D. 45,733,503 15,422,452 36,697,144”
Alector, Inc. reported the quarter ended March 31, 2026 results: revenue $1.0 million, net income $22.9 million, EPS $0.21 per share.
“Revenue. Collaboration revenue for the quarter ended March 31, 2026, was $1.0 million, compared to $3.7 million for the same period in 2025.”
Alector, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $125,000,000 (effective 2026-05-07).
“On May 7, 2026, Alector, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Sales Agreement ”) with TD Securities (USA) LLC (“ TD Cowen ”), pursuant to which the Company may offer and sell from time to time through TD Cowen up to $125,000,000 of shares”
Alector, Inc. announced a restructuring with charges of approximately $7.7 million affecting across the organization (approximately 75 employees).
“The Company initiated a reduction in force impacting approximately 75 employees across the organization. Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million.”
Grace Wong-Sarad was appointed as Vice President, Accounting at Alector, Inc..
“and Grace Wong-Sarad will be the Vice President, Accounting, serving as the principal accounting officer of Alector.”
Neil Berkley was appointed as Interim Chief Financial Officer at Alector, Inc..
“Effective upon Dr. Grasso’s resignation, Neil Berkley will be Chief Business Officer and Interim Chief Financial Officer, serving as the principal financial officer of Alector”
Marc Grasso resigned as Chief Financial Officer at Alector, Inc..
“On June 9, 2025, Dr. Marc Grasso gave notice of his decision to resign from his position as Chief Financial Officer of Alector, Inc. (“Alector”) in order to pursue other opportunities.”
Gary Romano resigned as Chief Medical Officer at Alector, Inc..
“On March 25, 2025, Dr. Gary Romano gave notice of his decision to resign from his position as Chief Medical Officer of Alector, Inc. (the “Company”) in order to pursue other opportunities.”
Alector, Inc. announced a restructuring with charges of approximately $2.4 million affecting the organization (approximately 25 employees).
“its operating expenses and capital expenditure requirements through 2026. One-time restructuring charges associated with the reduction in force are expected to be approximately $2.4 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits. Cash payments related to these expenses will be paid out and the”
Alector, Inc. announced a restructuring with charges of approximately $3.9 million (approximately 41 employees).
“On November 25, 2024, Alector, Inc. (“Alector” or “the Company”) committed to a plan to reduce its workforce (the “Plan”) by approximately 17% in order to align resources with the Company's strategic priorities. Based upon the results of the Company's INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in early Alzheimer’s disease, the Company is stopping the long term extension of the INVOKE-2 study. The Company initiated a reduction in force impacting approximately 41 employees across the organization. The Company continues to expect that its existing cash, cash equivalents and investments will enable it to fund its operating expenses and capital expenditure requirements through 2026. One-time restructuring charges associated with the reduction in force are expected to be approximately $3.9 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits.”
Alector, Inc. reported financial results for First Quarter 2024.
“Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates.”
Mark Altmeyer was appointed as Director at Alector, Inc..
“On March 19, 2024 (the “Appointment Date”), each of Errol De Souza, Ph.D. and Mark Altmeyer was appointed to the Board.”
Errol De Souza, Ph.D. was appointed as Director at Alector, Inc..
“On March 19, 2024 (the “Appointment Date”), each of Errol De Souza, Ph.D. and Mark Altmeyer was appointed to the Board.”
Terry McGuire resigned as Director at Alector, Inc..
“On March 15, 2024, Terry McGuire informed Alector, Inc. (the “Company”) of his resignation as a member of the Board of Directors (the “Board”) and all committees and subcommittees thereof, effective close of business March 20, 2024.”
Alector, Inc. reported financial results for the quarter ended December 31, 2023.
“On February 27, 2024, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2023.”
Alector, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at Issuance and sale of 10,869,566 shares of common stock at $6.57 per share, gross proceeds approximat (effective 2024-01-17).
“On January 17, 2024, Alector, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Cantor Fitzgerald & Co. (the "Underwriter"), relating to the issuance and sale (the "Offering") of 10,869,566 shares of the Company's common stock, par value $0.0001 per share, at a price per share of $6.57 to be paid by the Underwriter (the "Underwritten Shares").”
Alector, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $125,000,000 (effective 2023-11-07).
“On November 7, 2023, Alector, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Sales Agreement ”) with Cowen and Company, LLC (“ TD Cowen ”), pursuant to which the Company may offer and sell from time to time through TD Cowen up to $125,000,000 of shares”
Alector, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 7, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.”
Alector, Inc. reported the quarter ended June 30, 2023 results: revenue $56.2 million.
“quarter of 2023 covering AL002 compositions and methods of use. Second Quarter 2023 Financial Results Revenue. Collaboration revenue for the quarter ended June 30, 2023, was $56.2 million, compared to $79.9 million for the same period in 2022. The $23.6 million decrease was mainly due to $68.9 million of collaboration revenue recognized in the second quarter of”
Alector, Inc.: Amended and restated bylaws to enhance stockholder nomination procedures, adopt universal proxy rules, conform to DGCL amendments, update director/officer provisions, and make ministerial changes (effective 2023-06-15).
“On June 10, 2023, the Board of Directors (the “Board”) of Alector, Inc. (“Alector”) approved Alector’s Amended and Restated Bylaws (the “Bylaws”) effective as of June 15, 2023. The Bylaws were amended and restated to, among other things: • enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at Alector’s annual meeting of stockholders (except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), including by requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to a stockholder’s solicitation of proxies; • change certain provisions relating to stockholder nominees for election as a director to address the new “universal proxy rules” in accordance with Rule 14a-19 under the Exchange Act; • revise ce”
Alector, Inc. shareholders approved Advisory vote on executive compensation (Say-on-Pay) at the 2023-06-14 meeting.
“3. Stockholders approved, on a non-binding advisory basis, the compensation of Alector’s named executive officers as disclosed in the proxy statement for the Annual Meeting, known as the Say-on-Pay vote. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Vote 58,053,865 3,397,559 143,263 11,001,085”
Alector, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered accounting firm at the 2023-06-14 meeting.
“2. Stockholders ratified the appointment of Ernst & Young LLP as Alector’s independent registered accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Vote 72,466,471 64,571 64,730 0”
Alector, Inc. shareholders approved Election of Class II directors at the 2023-06-14 meeting.
“1. The Class II director nominees were elected to serve until Alector’s 2026 annual meeting of stockholders and until their successors are elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Vote Elizabeth Garofalo, M.D. 60,676,396 918,292 11,001,084 Terry McGuire 54,251,697 7,342,991 11,001,084 Kristine Yaffe, M.D. 54,111,053 7,483,635 11,001,084”
Alector, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 4, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.”
Tillman Gerngross resigned as Director at Alector, Inc..
“On April 25, 2023, Tillman Gerngross, Ph.D. informed Alector, Inc. (the “Company”) of his resignation as Chairperson of the Company’s board of directors (the “Board”), effective June 13, 2023, and his resignation as a director of the Board, effective June 15, 2023.”
Tillman Gerngross resigned as Chairperson at Alector, Inc..
“On April 25, 2023, Tillman Gerngross, Ph.D. informed Alector, Inc. (the “Company”) of his resignation as Chairperson of the Company’s board of directors (the “Board”), effective June 13, 2023, and his resignation as a director of the Board, effective June 15, 2023.”
Alector, Inc. announced a restructuring with charges of approximately $2.2 million affecting the organization (approximately 30 employees).
“multiple key clinical milestones for its prioritized late-stage programs. One-time restructuring charges associated with the reduction in force are expected to be approximately $2.2 million, primarily consisting of personnel expenses such as salaries, one-time severance payments, and other benefits. Cash payments related to these expenses will be paid out and the”
Alector, Inc. reported financial results for the quarter ended December 31, 2022.
“On February 28, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2022.”
Alector, Inc. reported the quarter ended September 30, 2022 results: revenue $14.9 million.
“research pipeline and helps drive business strategy. Third Quarter 2022 Financial Results Revenue. Collaboration revenue for the quarter ended September 30, 2022, was $14.9 million, compared to $182.4 million for the same period in 2021. The decrease of $167.6 mil”
Robert King resigned as Chief Development Officer at Alector, Inc..
“On October 3, 2022, Robert King, Ph.D., Chief Development Officer of Alector, Inc. (the “Company”), notified the Company of his decision to resign from his position, effective October 28, 2022, to pursue another professional opportunity.”
Gary Romano, Ph.D., M.D. was appointed as Chief Medical Officer at Alector, Inc..
“On March 29, 2022, Alector, Inc. (“Alector”) announced the appointment of Gary Romano, Ph.D., M.D., as Alector’s Chief Medical Officer , effective May 23, 2022.”
Linda Rubinstein changed role as interim Chief Financial Officer at Alector, Inc..
“Effective upon Dr. Grasso’s appointment on February 7, 2022, Ms. Linda Rubinstein will no longer serve as Alector’s interim Chief Financial Officer.”
Marc Grasso was appointed as Chief Financial Officer at Alector, Inc..
“On February 7, 2022, Alector, Inc. (“Alector”) announced the appointment of Marc Grasso, M.D. as Alector’s Chief Financial Officer.”
Shehnaaz Suliman resigned as President and Chief Operating Officer at Alector, Inc..
“On December 31, 2021, Alector, LLC, a subsidiary of Alector, Inc. (collectively, the “Company”) entered into an agreement (the “Separation Agreement”) with Shehnaaz Suliman, the Company’s President and Chief Operating Officer, completing the terms of Dr. Suliman’s previously announced voluntary separation from the Company.”
Saraswati (Sara) Kenkare-Mitra was appointed as President and Head of Research and Development at Alector, Inc..
“On December 15, 2021, Alector, Inc. (“Alector”) announced the appointment of Saraswati (Sara) Kenkare-Mitra, Ph.D. as Alector’s President and Head of Research and Development.”
Elizabeth A. Garofalo was appointed as Class II director at Alector, Inc..
“On September 23, 2021, Elizabeth A. Garofalo, M.D. was appointed to the Board of Directors (the “Board”) of Alector, Inc. (the “Company”).”
Calvin Yu changed role as Vice President, Finance at Alector, Inc..
“In conjunction with Ms. Rubinstein’s appointment, Mr. Calvin Yu will no longer serve as Alector’s Principal Financial Officer or Principal Accounting Officer. He will continue to serve as Alector’s Vice President, Finance.”
Linda Rubinstein was appointed as Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Alector, Inc..
“On September 8, 2021, Alector, Inc. (“Alector”) appointed Linda Rubinstein as Alector’s interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.”
Robert Paul changed role as Chief Medical Officer at Alector, Inc..
“on September 7, 2021, the Company entered into a letter agreement (the “Letter Agreement”) with Robert Paul, the Company’s Chief Medical Officer, setting forth the terms of Dr. Paul’s voluntary transition from the Company.”
Shehnaaz Suliman changed role as President and Chief Operating Officer at Alector, Inc..
“On September 7, 2021, Alector, LLC, a subsidiary of Alector, Inc. (collectively, the “Company”) entered into an agreement (the “Transition Agreement”) with Shehnaaz Suliman, the Company’s President and Chief Operating Officer, setting forth the terms of Dr. Suliman’s voluntary transition from the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.